INDIANAPOLIS, Nov. 13, 2024 /PRNewswire/ -- Eli Lilly and Company (LLY) announced today detailed results from the Phase 3 SURMOUNT-1 three-year study (176-week treatment period), the longest completed ...

Concurrent hormone therapy may augment the cardiometabolic benefits of tirzepatide, including improved blood pressure and lipid profiles.

The workshop featured invited presentations and discussions that explore what is known about current obesity treatment approaches and the challenges involved in implementing them, including their ...

More adults are taking GLP-1 drugs to control their weight, despite recent shortages and high list prices, according to new research. The percentage of overweight or obese adults prescribed a GLP-1 ...

Evidence suggests that incretin-based dual agonist pharmacotherapy is helpful in persons with obesity. Mazdutide, a glucagon-like peptide-1 and glucagon receptor dual agonist, may have efficacy in ...

Compared to traditional dietary advice (like restricting calories or eating different types of foods), intermittent fasting may make little to no difference to weight loss and quality of life in ...

Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the landmark TOGETHER-PsO open-label Phase 3b ...

Children and adolescents with Crohn disease with a high body mass index may require a higher dose of adalimumab. Pediatric patients with Crohn disease (CD) with a high body mass index (BMI) are more ...

The workshop featured invited presentations and discussions that explore what is known about current obesity treatment approaches and the challenges involved in implementing them, including their ...